We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Breast Cancer in Postmenopausal Women After Hormone Therapy

Rod Baber, MBBS, BPharm
JAMA. 2011;305(5):466-467. doi:10.1001/jama.2011.74.
Text Size: A A A
Published online


To the Editor: Dr Chlebowski and colleagues, in their follow-up of the Women's Health Initiative (WHI),1 showed an increase in breast cancer mortality for women randomized to estrogen plus progestin compared with placebo of 1.3 per 10 000 women per year. Also, longer follow-up data on de novo hormone therapy users in the trial confirmed no increased risk of breast cancer incidence. The WHI commenced in the 1990s and ceased in 2002, and the risks and benefits described relate to a regimen of hormone therapy rarely used in the United States in 2010. Lower doses, different estrogens and progestins, and different regimens are now more commonly prescribed. As Dr Bach2 points out in the accompanying Editorial, more evidence is needed, but on outcomes related to newer regimens.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




February 2, 2011
R. Kent Hermsmeyer, PhD; Juan Carlos Kaski, MD, DM(Hons), DSc; Theresa L. Thompson, PhD
JAMA. 2011;305(5):466-467. doi:10.1001/jama.2011.75.
February 2, 2011
Rowan T. Chlebowski, MD, PhD; Marcia L. Stefanick, PhD; Garnet L. Anderson, PhD
JAMA. 2011;305(5):466-467. doi:10.1001/jama.2011.76.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.